| # | Drug | Count |
|---|---|---|
| 0 | CERTOLIZUMAB PEGOL | 38 |
| 1 | METHOTREXATE SODIUM | 37 |
| 2 | METHOTREXATE | 33 |
| 3 | RITUXIMAB | 29 |
| 4 | ADALIMUMAB | 23 |
| 5 | HYDROXYCHLOROQUINE SULFATE | 17 |
| 6 | IBUPROFEN | 16 |
| 7 | ETANERCEPT | 15 |
| 8 | IBUPROFEN AND DIPHENHYDRAMINE CITRATE | 15 |
| 9 | TOCILIZUMAB | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | VARDENAFIL HYDROCHLORIDE | 5 | 0.0610 |
| 1 | VORETIGENE NEPARVOVEC-RZYL | 2 | 0.0132 |
| 2 | LUMASIRAN | 1 | 0.0026 |
| 3 | VARDENAFIL | 1 | 0.0017 |
| 4 | GOLD | 8 | 0.0014 |
| 5 | BROLUCIZUMAB | 5 | 0.0014 |
| 6 | PEMIGATINIB | 1 | 0.0012 |
| 7 | ERDAFITINIB | 1 | 0.0008 |
| 8 | VERTEPORFIN FOR INJECTION | 1 | 0.0007 |
| 9 | IBUPROFEN AND DIPHENHYDRAMINE CITRATE | 15 | 0.0006 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Erythroid Maturation Agent [EPC] | 1 | 0.0004 |
| 1 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 2 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 2 | 0.0003 |
| 3 | Photoenhancer [EPC] | 1 | 0.0003 |
| 4 | Carbonic Anhydrase Inhibitor [EPC] | 3 | 0.0001 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 21 | 0.0001 |
| 6 | Tissue-nonspecific Alkaline Phosphatase [EPC] | 1 | 0.0001 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 30 | 0.0001 |
| 8 | Interleukin-6 Receptor Antagonist [EPC] | 13 | 0.0001 |
| 9 | Protease Inhibitor [EPC] | 4 | 0.0001 |